Ian Abercrombie

Ian Abercrombie had an extensive career in the pharmaceutical industry. Ian served as the Chief Executive Officer of Medannex Ltd from July 2019 onwards. Prior to that, they were the Chief Operating Officer at NuCana BioMed, where they played a crucial role in developing and commercializing the protide technology platform for oncology treatments. Ian held the position from April 2012 until their departure.

Before joining NuCana BioMed, Ian served as the VP Operations (EU/International) at Caris Life Sciences from August 2010 to April 2012. Ian also gained valuable experience as the European Director of Oncology at Genzyme from October 2007 to August 2010 and as a Programme Director at bioenvision from January 2002 to October 2007.

Ian Abercrombie began their career in the pharmaceutical industry at Johnson & Johnson, where they held the position of Regional Director (oncology) from October 1995 to January 2002.

Ian Abercrombie attended Glasgow Caledonian University from 1990 to 1995. No specific degree or field of study was mentioned for this period.